24.32 0.00 (0.00%)
After hours: 4:42PM EST
|Bid||24.00 x 1400|
|Ask||24.40 x 400|
|Day's range||22.75 - 25.02|
|52-week range||7.37 - 25.02|
|PE ratio (TTM)||N/A|
|Earnings date||7 Mar 2018 - 12 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||24.00|
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has closed the transactions contemplated by its commercialization agreement (the “Agreement”) with Depomed, Inc. (“Depomed”) pursuant to which Collegium has the right to commercialize Nucynta® (tapentadol) Immediate Release and Nucynta® ER (tapentadol) Extended Release tablets in the United States. The transaction is expected to be immediately accretive and to significantly increase product revenue. Upon closing, Collegium paid an upfront license fee of $10.0 million, as well as a cash payment equal to $6.2 million for Depomed’s cost of inventory with greater than twelve months dating.
“We are pleased to finalize this agreement which has a compelling strategic logic for both companies,” said Arthur Higgins, President and CEO of Depomed. As previously announced, on December 4, 2017, Depomed signed a definitive Commercialization Agreement with Collegium under the terms of which, Collegium will commercialize NUCYNTA and in exchange Depomed will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds.
Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.
The boost to U.S. stocks from tax-reform proved short-lived, with the Dow Jones Industrial Average finishing up less than 60 points, while the Nasdaq Composite and S&P 500 closed down 1.1% and 0.1%, respectively. The negative momentum has spilled over into Asia-Pacific markets with benchmark indices in Australia, Japan and Korea all in the red on Tuesday morning. In U.S. after-hours stock news: Collegium Pharmaceutical (COLL) jumped 9% after announcing that it has entered into a definitive agreement with Depomed to commercialize Nucynta tablets in the U.S. Depomed (DEPO) jumped 4.9% on the same agreement. Ascena Retail Group (ASNA) slumped 20% after the fashion retailer posted a 50% year--on-year drop in FY18 first quarter earnings and offered weak guidance for the upcoming quarter.
DepoMed Inc. announced Monday afternoon that it will allow Collegium Pharmaceutical Inc. to handle sales of its most lucrative product, the Nucynta line of painkillers, and slash its workforce. DepoMed ...
The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 45 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...